Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia.

@article{Shulman2002VirtualIQ,
  title={Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia.},
  author={Nancy S Shulman and Andrew Zolopa and Diane Havlir and Ann F Hsu and Cheryl L Renz and Sheila Boller and Ping Jiang and Richard A Rode and Joel E. Gallant and Elizabeth Race and Dale J. Kempf and Eugene F Sun},
  journal={Antimicrobial agents and chemotherapy},
  year={2002},
  volume={46 12},
  pages={3907-16}
}
Depending on the degree of underlying resistance present, optimization of the pharmacokinetics of protease inhibitors may result in improved virologic suppression. Thirty-seven human immunodeficiency virus (HIV)-infected subjects who had chronic detectable viremia and who were receiving 800 mg of indinavir three times a day (TID) were switched to 400 mg of indinavir BID with 400 mg of ritonavir two times a day (BID) for 48 weeks. Full pharmacokinetic evaluations were obtained for 12 subjects… CONTINUE READING